No Data
Jiangxi Synergy Pharmaceutical (300636.SZ): The Active Pharmaceutical Ingredient Empagliflozin has passed the Pharmaceutical GMP compliance inspection.
On March 11, Gdonghui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) announced it has recently received the "Notification of the Compliance Inspection Results for Pharmaceutical GMP from the Jiangxi Provincial Drug Administration (Gan Pharmaceutical GMP (2025) No. A0020)". Following on-site inspection and comprehensive assessment, it was found that the Active Pharmaceutical Ingredient, Empagliflozin, complies with pharmaceutical GMP. Empagliflozin is used for the treatment of type 2 diabetes.
Jiangxi Synergy Pharmaceutical Secures Drug Registration in South Korea
Jiangxi Synergy Pharmaceutical (300636.SZ): The Mirabegron product has obtained a pharmaceutical registration certificate in South Korea.
On February 17th, Gelonghui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) announced that it recently received the pharmaceutical registration certificate for Mirabegron issued by the South Korean Ministry of Food and Drug Safety (MFDS). Mirabegron is a selective β3-adrenoceptor agonist that can enhance bladder filling and storage capacity by activating β3-adrenoceptors on the bladder detrusor, and is clinically used for treating symptoms of overactive bladder such as urgency, frequent urination, and incontinence.
Jiangxi Synergy Pharma's Celecoxib Gets EU Marketing Nod
Jiangxi Synergy Pharmaceutical (300636.SZ): Sales of new varieties will continue to grow in 2025.
On January 8, Gelonghui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) recently stated in an investor relations activity that the sales performance of new products in Q4 was better than in Q3, and the sales of new products will continue to grow in 2025, with growth in the high-end market surpassing that of Emerging Markets.
Jiangxi Synergy Pharmaceutical (300636.SZ): It is expected that the production capacity utilization rate of Phase I of the second factory will exceed 60% in 2025.
On January 8, Gelonghui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) stated during a recent investor relation activity that the capacity utilization rate of Phase I of the second factory area in the second half of 2024 is around 60% (officially starting production in the second half of the year), and it is expected that the capacity utilization rate will exceed 60% in 2025; all seven workshops of Phase II of the second factory area have completed civil construction, with the installation of equipment starting in two workshops after the Spring Festival, and it is expected that production capacity will be formed in the fourth quarter of 2025.
Risks Still Elevated At These Prices As Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Shares Dive 28%
